Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
scPharmaceuticals Inc. See All Filings	D	2017-01-06 16:08:30 UTC
Amount To Be Raised $46,962,788 Associated Brokers / Dealers N/A CIK Number 0001604950 Filed Document 0001604950-17-000001 Exclusions or Exemptions 506b Accepted Date 2017-01-06 16:08:30 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
scPharmaceuticals Inc. See All Filings	D	2016-09-06 13:23:33 UTC
Amount To Be Raised $10,000,000 Associated Brokers / Dealers N/A CIK Number 0001604950 Filed Document 0001604950-16-000003 Exclusions or Exemptions 506b Accepted Date 2016-09-06 13:23:33 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Debt
scPharmaceuticals Inc. See All Filings	D	2016-09-06 13:16:52 UTC
Amount To Be Raised $8,183,797 Associated Brokers / Dealers N/A CIK Number 0001604950 Filed Document 0001604950-16-000002 Exclusions or Exemptions 506b Accepted Date 2016-09-06 13:16:52 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
scPharmaceuticals Inc. See All Filings	D	2016-02-04 00:00:00 UTC
Amount To Be Raised $7,500,000 Associated Brokers / Dealers N/A CIK Number 0001604950 Filed Document 0001604950-16-000001 Exclusions or Exemptions 506b Accepted Date 2016-02-04 00:00:00 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Debt
scPharmaceuticals Inc. See All Filings	D	2014-04-07 00:00:00 UTC
Amount To Be Raised $17,053,016 Associated Brokers / Dealers N/A CIK Number 0001604950 Filed Document 0001604950-14-000001 Exclusions or Exemptions 506b Accepted Date 2014-04-07 00:00:00 UTC Type of Offering D Industry Biotechnology Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity